A Biomarker for Predicting Responsiveness to Stem Cell Therapy Based on Mechanism-of-Action: Evidence from Cerebral...

Area of Science:

• Regenerative Medicine
• Neuroscience
• Biomarker Development

Background:

• Current stem cell therapies lack recipient-specific selection criteria.
• Perinatal/neonatal hypoxic-ischemic injury (HII) is a significant neurological challenge.
• Identifying patients who will benefit from neural stem cell therapy is critical.

Purpose of the Study:

• To develop a noninvasive biomarker for selecting HII patients for human neural stem cell (hNSC) therapy.
• To correlate imaging biomarkers with hNSC therapeutic mechanisms of action (MOA).
• To establish criteria for optimal patient selection in regenerative medicine.

Main Methods:

• Utilized a clinically translatable magnetic resonance imaging (MRI) algorithm (hierarchical region splitting).
• Assessed lesion characteristics (penumbra vs. core) to predict response to hNSCs.
• Evaluated the neuroprotective MOA of hNSCs in a preclinical HII model.

Main Results:

• The MRI algorithm successfully identified lesions with a molecular profile responsive to hNSCs.
• hNSC therapy improved outcomes only in subjects with an MRI-measurable penumbra.
• Lesions with a larger core volume than penumbra did not benefit from hNSC treatment.

Conclusions:

• A noninvasive MRI-based biomarker can prospectively identify patients suitable for hNSC therapy for HII.
• This approach represents a significant advancement in personalized regenerative medicine.
• Selection based on penumbral volume is crucial for effective stem cell treatment in HII.